Bacterial ghosts as vaccine candidates for veterinary applications

Journal of Controlled Release

Volumn 85, Issue 1-3, 2002, Pages 17-25

  Jalava, Katri ^a   Hensel, Andreas ^b   Szostak, Michael ^a   Resch, Stephanie ^c   Lubitz, Werner ^a,d  

^a BIRD C GmbH and CoKEG   (Austria)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Apovia AG   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bacterial ghosts; Mucosal immunity; Vaccines

Indexed keywords

PROTEIN; VACCINE; BACTERIAL VACCINE; VETERINARY DRUG;

ACTINOBACILLUS PLEUROPNEUMONIAE; BACTERIAL STRAIN; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC REGULATION; GRAM NEGATIVE BACTERIUM; IMMUNOCONTRACEPTION; KLEBSIELLA PNEUMONIAE; MOLECULAR BIOLOGY; MYCOPLASMA; MYCOPLASMA BOVIS; NONHUMAN; PASTEURELLA MULTOCIDA; PRIORITY JOURNAL; PSEUDORABIES; REVIEW; SEROTYPE; VETERINARY MEDICINE; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METHODOLOGY; SYNTHESIS;

ANIMALS; BACTERIAL VACCINES; DRUG DELIVERY SYSTEMS; GRAM-NEGATIVE BACTERIA; HUMANS; VETERINARY DRUGS;

EID: 0037073664     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00267-5     Document Type: Review

References (38)

1. Szostak M.P., Hensel A., Eko F.O., Klein R., Auer T., Mader H., Haslberger A., Bunka S., Wanner G., Lubitz W. Bacterial ghosts: nonliving candidate vaccines. J. Biotechnol. 44:1996;161-170.
2. Lubitz W., Witte A., Eko F.O., Kamal M., Jechlinger W., Brand E., Marchart J., Haidinger W., Huter V., Felnerova D., Stralis-Alves N., Lechleitner S., Melzer H., Szostak M.P., Resch S., Mader H., Kuen B., Mayr B., Mayrhofer P., Geretschläger R., Haslberger A., Hensel A. Extended recombinant bacterial ghost system. J. Biotech. 73:1999;261-273.
3. Szostak M.P., Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles. Channock R.M., Ginsberg H.S., Brown F., Lerner R.A. Vaccines 91: Modern Approaches to New Vaccines Including Prevention of AIDS. 1991;409-414 Cold Spring Harbor Laboratory Press, New York.
4. Jechlinger W., Szostak M., Lubitz W. Cold-sensitive E-lysis systems. Gene. 218:1998;1-7.
5. Jechlinger W., Szostak M., Witte A., Lubitz W. Altered temperature induction sensitivity of the lambda PR/cI857 system for controlled gene E-expression in Escherichia coli. FEMS Microbiol. Lett. 173:1999;347-352.
6. Ronchel M.C., Molina L., Lubitz W., Molin S., Ramos J.L., Ramos C. Characterization of cell lysis in Pseudomonas putida induced upon expression of heterologous killing genes. Appl. Environ. Microbiol. 64:1998;4904-4911.
7. Witte A., Wanner G., Sulzner M., Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol. 157:(4):1992;381-388.
8. Witte A., Wanner G., Blasi U., Halfmann G., Szostak M., Lubitz W. Endogenous transmembrane tunnel formation mediated by PhiX174 lysis protein E. J. Bacteriol. 172:(7):1990;4109-4114.
9. Witte A., Blasi U., Halfmann G., Szostak M., Wanner G., Lubitz W. Phi X174 protein E-mediated lysis of Escherichia coli. Biochimie. 72:(2-3):1990;191-200.
10. Lubitz W., Pugsley A.P. Changes in cell phospholipid composition of PhiX174 gene E product. FEMS Microbiol Lett. 30:1985;171-175.
11. Witte A., Wanner G., Lubitz W., Höltje J.-V. Effect of PhiX174 protein E-mediated lysis on murein composition of Escherichia coli. FEMS Microbiol. Lett. 164:1998;149-157.
12. Witte A., Brand E., Mayrhofer P., Narendja F., Lubitz W. Dependence of PhiX174 protein E-mediated lysis on cell division activities of Escherichia coli. Arch. Microbiol. 170:1998;259-268.
13. Witte A., Brand E., Schrot G., Lubitz W. Pathway of PhiX174 protein E mediated lysis of Escherichia coli. de Pedro M.A., Hoeltje J.-V., Loeffelhardt W. Bacterial Growth and Lysis-Metabolism and Structure of the Bacterial Sacculus. 1993;277-283 Plenum Press, New York.
14. Bernhard T.G., Roof W.D., Young R. Genetic evidence that the bacteriophage PhiX174 lysis protein inhibits cell wall synthesis. Proc. Natl. Acad. Sci. USA. 97:2000;4297-4302.
15. Hensel A., van Leengoed L.A.G., Szostak M., Windt H., Weissenböck H., Stockhofe-Zurwieden N., Katinger A., Stadler M., Ganter M., Bunka S., Pabst R., Lubitz W. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J. Biotechnol. 44:1996;171-181.
16. Katinger A., Lubitz W., Szostak M.P., Stadler M., Klein R., Indra A., Huter V., Hensel A. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotech. 73:1999;251-260.
17. Hensel A., Huter V., Katinger A., Raza P., Strnistschie C., Brand E., Roesler U., Lubitz W. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine. 18:2000;2945-2955.
18. Huter V., Hensel A., Brand E., Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 83:2000;161-172.
19. Haslberger A., Kohl G., Felnerova D., Mayr U.B., Fürst-Ladani S., Lubitz W. Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells. J. Biotechnol. 83:2000;57-66.
20. Knight D.P., Pane J., Seller D. A selective medium for Pasteurella multocida and its use with animal and human species. Clin. Pathol. 36:1983;591-594.
21. Rutter J.M. Pasteurella multocida. Adlam C. Pasteurella and Pasteurellosis. 1989;37-75 Academic Press, San Diego.
22. Kasten R.W., Hansen L.M., Hinojoza J., Bieber D., Ruehl W.W., Hirsch D.C. P. multocida produces a protein with homology to the P6 outer membrane protein of Haemophilus influenzae. Infect. Immun. 63:(3):1995;989-993.
23. Nencioni L., Pizza M., Bugnoli M., De Magistris T., Di Tommaso A., Giovanni F., Manetti R., Marsisli I., Nucci G. Characterisation of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping caught. Infect. Immun. 58:1990;1308-1315.
24. J. Marchrart, Pasteurella combination vaccines, Ph.D. Thesis, University of Vienna, Austria (2001).
25. Sojka W.J., Carnaghan R.B.A. Escherichia coli infection in poultry. Res. Vet. Sci. 2:1961;340-352.
26. Panigraphy B., Gyimah J.E., Hall C.F., Williams J.D. Immunogenic potency of an oil-emulsified E. coli bacterin. Avian Dis. 28:1984;475-481.
27. Truppe M., Horworka S., Schroll G., Lechleitner S., Kuen B., Resch S., Lubitz W. Biotechnological applications of recombinant S-layer proteins rSbsA and rSbsB from Bacillus stearothermophilus PV72. FEMS Microbiol. Rev. 20:1997;88-98.
28. J. Duckworth, K. Mate, S. Scobie, D. Jones, J. Buist, F. Molinia, A. Glazier, X Cui, P. Cowan, A. Walmsley, D. Kirk, W. Lubitz, C. Haller, Evaluating zona pellucida antigens and delivery systems for possum fertility control in New Zealand - progress and future directions, in: Biological management of possums: National Science Strategy Committee for Possum and Bovine Tb Control, 2-4 April 2001. Wellington, Ministry of Agriculture and Forestry. www.maf.govt.nz/mafnet/publications/research/biological-management-of- possums.
29. Wittmann G., Rziha H.J. Aujeszky's disease (pseudorabies) in pigs. Wittmann G. Herpesvirus Disease in Cattle, Horses, Pigs. 1989;230-325 Kluwer, Boston.
30. Roizman B., Sears S. Herpesviridae. Fields B.N. Virology. 2nd Edition:1990;1787-1793 Raven Press, New York.
31. Simecka J.W., Davis J.K., Davidson M.K., Ross S.E., Städtlander C.K., Cassell G.H. Mycoplasma diseases of animals. Maniloff J. Mycoplasmas - molecular Biology and Pathogenesis. 1992;391-415 American Society for Microbiology, Washington, DC.
32. Barile M.F. Immunization against mycoplasma infections. Razin S., Whitcomb R.F. The Mycoplasma, Mycoplasma Pathogenicity. Vol. 4:1985;451-492 Academic Press, Orlando, FL.
33. Behrens A., Heller M., Kirchhoff H., Yogev D., Rosengarten R. A family of phase-, and size-variant membrane surface lipoprotein antigens (Vsps) of Mycoplasma bovis. Infect. Immun. 62:1994;5075-5084.
34. Lysnyansky I., Rosengarten R., Yogev D. Phenotypic switching of variable surface lipoproteins in Mycoplasma bovis involves high-frequency chromosomal rearrangements. J. Bacteriol. 178:1996;5395-5401.
35. Haslberger A., Mader H.J., Schmalnauer M., Kohl G., Messner P., Sleytr U.B., Wanner G., Fürst-Ladani S., Lubitz W. Bacterial cell envelopes (ghosts) and LPS but not bacterial S-layers induce synthesis of immune-mediators in mouse macrophages involving CD14. J. Endotox. Res. 4:1997;431-441.
36. Mader H.J., Szostak M.P., Hensel A., Lubitz W., Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccine. Vaccine. 15:1997;195-202.
37. Lubitz W. Bacterial ghosts as carrier and targeting systems. Exp. Opin. Biol. Ther. 1:2001;765-771.
38. Huter V., Szostak M.P., Gampfer J., Prethaler S., Wanner G., Gabor F., Lubitz W. Bacterial ghosts as drug carrier and targeting vehicles. J. Control. Release. 61:1999;51-63.